The role of pathogen‐reduced platelet transfusions on HLA alloimmunization in hemato‐oncological patients

Platelet transfusions can induce alloimmunization against HLA antigens. The use of pathogen‐reduced platelet concentrates (PCs) was suggested to reduce HLA alloimmunization and concomitant transfusion refractoriness.

[1]  T. Hervig,et al.  Hemostatic efficacy of pathogen-inactivated-versus untreated-platelets : a randomized controlled trial , 2018 .

[2]  A. ten Brinke,et al.  Storage-Induced Platelet Apoptosis Is a Potential Risk Factor for Alloimmunization Upon Platelet Transfusion , 2018, Front. Immunol..

[3]  B. Custer,et al.  Ultraviolet light‐based pathogen inactivation and alloimmunization after platelet transfusion: results from a randomized trial , 2018, Transfusion.

[4]  J. Tuimala,et al.  Platelet donor selection for HLA‐immunised patients; the impact of donor‐specific HLA antibody levels , 2017, Transfusion medicine.

[5]  Y. Latchman,et al.  Leukofiltration plus pathogen reduction prevents alloimmune platelet refractoriness in a dog transfusion model. , 2017, Blood.

[6]  D. Devine,et al.  Altered timing of riboflavin and ultraviolet light pathogen inactivation improves platelet in vitro quality , 2017, Transfusion.

[7]  P. Rebulla.  Klinische Effektivität von pathogeninaktivierten Thrombozytenkonzentraten , 2017, Transfusionsmedizin - Immunhämatologie, Hämotherapie, Immungenetik, Zelltherapie.

[8]  M. Graf,et al.  Clinical effectiveness of platelets in additive solution treated with two commercial pathogen‐reduction technologies , 2017, Transfusion.

[9]  M. Muench,et al.  Reduced MHC alloimmunization and partial tolerance protection with pathogen reduction of whole blood , 2017, Transfusion.

[10]  D. Devine,et al.  Experiences with semi‐routine production of riboflavin and UV‐B pathogen‐inactivated platelet concentrates in three blood centres , 2017, Vox sanguinis.

[11]  J. Voorberg,et al.  Evaluation of the role of the GPIb‐IX‐V receptor complex in development of the platelet storage lesion , 2016, Vox sanguinis.

[12]  Y. Latchman,et al.  Ultraviolet B irradiation in the prevention of alloimmunization in a dog platelet transfusion model , 2016, Transfusion.

[13]  A. Seltsam,et al.  Effect of increased agitation speed on pathogen inactivation efficacy and in vitro quality in UVC‐treated platelet concentrates , 2016, Vox sanguinis.

[14]  G. Berlin,et al.  Treatment of platelet concentrates with ultraviolet C light for pathogen reduction increases cytokine accumulation , 2016, Transfusion.

[15]  M. Muench,et al.  Reduced alloimmunization in mice following repeated transfusion with pathogen‐reduced platelets , 2016, Transfusion.

[16]  T. Hervig,et al.  A study protocol for a randomised controlled trial evaluating clinical effects of platelet transfusion products: the Pathogen Reduction Evaluation and Predictive Analytical Rating Score (PREPAReS) trial , 2016, BMJ Open.

[17]  L. Estcourt,et al.  Platelet refractoriness – practical approaches and ongoing dilemmas in patient management , 2015, British journal of haematology.

[18]  V. Compernolle,et al.  Ultraviolet C light pathogen inactivation treatment of platelet concentrates preserves integrin activation but affects thrombus formation kinetics on collagen in vitro , 2015, Transfusion.

[19]  T. Yoshizato,et al.  Effects of universal vs bedside leukoreductions on the alloimmunization to platelets and the platelet transfusion refractoriness. , 2015, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[20]  Tatsuki Koyama,et al.  Red blood cell alloimmunization is influenced by recipient inflammatory state at time of transfusion in patients with sickle cell disease , 2013, British journal of haematology.

[21]  L. Gutiérrez,et al.  Pathogen reduction treatment using riboflavin and ultraviolet light impairs platelet reactivity toward specific agonists in vitro , 2014, Transfusion.

[22]  D. Devine,et al.  Riboflavin and ultraviolet light treatment of platelets triggers p38MAPK signaling: inhibition significantly improves in vitro platelet quality after pathogen reduction treatment , 2013, Transfusion.

[23]  M. Muench,et al.  Immune modulation and lack of alloimmunization following transfusion with pathogen‐reduced platelets in mice , 2013, Transfusion.

[24]  K. Robinson,et al.  The mean fluorescence intensities of anti‐HLA antibodies detected using micro‐bead flow cytometry predict the risk of platelet transfusion refractoriness , 2012, British journal of haematology.

[25]  A. Seltsam,et al.  Update on the use of pathogen‐reduced human plasma and platelet concentrates , 2013, British journal of haematology.

[26]  M. Busch,et al.  Low-level HLA antibodies do not predict platelet transfusion failure in TRAP study participants. , 2013, Blood.

[27]  D. Marks,et al.  In vitro assessment of buffy‐coat derived platelet components suspended in SSP+ treated with the INTERCEPT Blood system , 2013, Transfusion medicine.

[28]  J. Freedman,et al.  HLA alloimmunization against platelet transfusions: pathophysiology, significance, prevention and management. , 2012, Tissue antigens.

[29]  J. Seghatchian,et al.  Characteristics of the THERAFLEX UV-Platelets pathogen inactivation system - an update. , 2012, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[30]  E. Hod,et al.  Transfusion in the absence of inflammation induces antigen-specific tolerance to murine RBCs. , 2012, Blood.

[31]  M. Muench,et al.  Prevention of Alloimmunization and Induction of Partial Tolerance Following Transfusion with Pathogen Reduced Platelets in Mice , 2011 .

[32]  D. Wright,et al.  Establishing assay cutoffs for HLA antibody screening of apheresis donors , 2011, Transfusion.

[33]  S. Marschner,et al.  Inactivation of human white blood cells in platelet products after pathogen reduction technology treatment in comparison to gamma irradiation , 2011, Transfusion.

[34]  S. Slichter,et al.  White blood cell inactivation after treatment with riboflavin and ultraviolet light , 2010, Transfusion.

[35]  H. Falet,et al.  Novel clearance mechanisms of platelets , 2010, Current opinion in hematology.

[36]  P. Mintz,et al.  A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology , 2010, Transfusion.

[37]  S. Kleinman,et al.  Identification of specificities of antibodies against human leukocyte antigens in blood donors , 2010, Transfusion.

[38]  D. Devine,et al.  The platelet storage lesion. , 2010, Clinics in laboratory medicine.

[39]  C. Hillyer,et al.  The effect of previous pregnancy and transfusion on HLA alloimmunization in blood donors: implications for a transfusion‐related acute lung injury risk reduction strategy , 2009, Transfusion.

[40]  P. Norris,et al.  IMMUNOHEMATOLOGY: Understanding loss of donor white blood cell immunogenicity after pathogen reduction: mechanisms of action in ultraviolet illumination and riboflavin treatment , 2009, Transfusion.

[41]  J. Eikenboom,et al.  The clinical impact of platelet refractoriness: correlation with bleeding and survival , 2008, Transfusion.

[42]  B. Gathof,et al.  Effects of Mirasol PRT treatment on storage lesion development in plasma‐stored apheresis‐derived platelets compared to untreated and irradiated units , 2008, Transfusion.

[43]  C. Koh,et al.  Treatment With Riboflavin and Ultraviolet Light Prevents Alloimmunization to Platelet Transfusions and Cardiac Transplants , 2007, Transplantation.

[44]  R. Goodrich,et al.  Mirasol PRT treatment of donor white blood cells prevents the development of xenogeneic graft‐versus‐host disease in Rag2–/–γc–/– double knockout mice , 2006, Transfusion.

[45]  J. Akkerman,et al.  Platelet binding and phagocytosis by macrophages , 2006, Transfusion.

[46]  R. Goodrich,et al.  Functional inactivation of white blood cells by Mirasol treatment , 2006, Transfusion.

[47]  I. López-Vílchez,et al.  Effects of a new pathogen‐reduction technology (Mirasol PRT) on functional aspects of platelet concentrates , 2005, Transfusion.

[48]  Edward J. Lee,et al.  Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. , 2005, Blood.

[49]  John J Spinelli,et al.  Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness. , 2004, Blood.

[50]  A. Lazarus,et al.  Role of Fcgamma receptors in the pathogenesis and treatment of idiopathic thrombocytopenic purpura. , 2003, Journal of pediatric hematology/oncology.

[51]  K. Schulman,et al.  Platelet transfusions: Utilization and associated costs in a tertiary care hospital , 2000, American journal of hematology.

[52]  J. Freedman,et al.  Unique processing pathways within recipient antigen-presenting cells determine IgG immunity against donor platelet MHC antigens. , 2000, Blood.

[53]  R. Kekomäki,et al.  Use of HLA‐ and HPA ‐ Matched Platelets in Alloimmunized Patients , 1998, Vox sanguinis.

[54]  Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. , 1997, The New England journal of medicine.

[55]  M. McConnell,et al.  Platelet refractoriness and alloimmunization in pediatric oncology and bone marrow transplant patients , 1995, Transfusion.

[56]  J. Freedman,et al.  Indirect allorecognition of platelets by T helper cells during platelet transfusions correlates with anti-major histocompatibility complex antibody and cytotoxic T lymphocyte formation. , 1995, Blood.

[57]  J. Hutton,et al.  Transfusion of ABO‐mismatched platelets leads to early platelet refractoriness , 1990, British journal of haematology.